Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Accession Therapeutics Limited, headquartered in Oxford, UK, is advancing first?in?class immuno-oncology therapies via its proprietary TROCEPT platform. Their lead candidate, TROCEPT?01 (ATTR?01), an engineered tumour-selective virus delivering immune checkpoint inhibitors, entered Phase 1/2 human trials (ATTEST) in early 2025. TROCEPT?02, a bispecific immune activator, is slated for clinical studies in 2026.

List your booth number for exhibitions, ask us